Discontinuation of preventive treatment for episodic migraine and chronic migraine: results from the international burden of migraine-ii study (ibms-ii)

被引：0
|
作者：
Becker, W. J. [1 ]
Buse, D. C. [2 ,3 ]
Lipton, R. B. [2 ,3 ]
Bloudek, L. M. [4 ]
Maglinte, G. A. [4 ]
Varon, S. F. [4 ]
Wilcox, T. K. [5 ]
Kawata, A. K. [5 ]
Blumenfeld, A. M. [6 ]
机构：
[1] Univ Calgary, Calgary, AB, Canada
[2] Albert Einstein Coll Med, Bronx, NY 10467 USA
[3] Montefiore Headache Ctr, Bronx, NY USA
[4] Allergan Pharmaceut Inc, Irvine, CA USA
[5] United BioSource Corp, Bethesda, MD USA
[6] Neurol Ctr, Encinitas, CA USA
来源：
CEPHALALGIA | 2011年 / 31卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PS1-19
引用
收藏
页码：28 / 28
页数：1
相关论文
共 50 条
  • [21] Headache Impact of Chronic and Episodic Migraine: Results From the American Migraine Prevalence and Prevention Study
    Buse, Dawn
    Manack, Aubrey
    Serrano, Daniel
    Reed, Michael
    Varon, Sepideh
    Turkel, Catherine
    Lipton, Richard
    HEADACHE, 2012, 52 (01): : 3 - 17
  • [22] Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine: Results from the TANDEM study
    Ailani, Jessica
    Lipton, Richard B.
    Blumenfeld, Andrew M.
    Mechtler, Laszlo
    Klein, Brad C.
    He, Molly Yizeng
    Smith, Jonathan H.
    Trugman, Joel M.
    Ferreira, Rosa de Abreu
    Brand-Schieber, Elimor
    HEADACHE, 2024,
  • [23] Atogepant for the Preventive Treatment of Migraine Among Participants With Episodic Migraine With Prior Treatment Failure: Results From the ELEVATE Trial
    Pozo-Rosich, Patricia
    Nagy, Krisztian
    Tassorelli, Cristina
    Lanteri-Minet, Michel
    Sacco, Sara
    Nezadal, Tomas
    Finnegan, Michelle
    Guo, Hua
    Ferreira, Rosa De Abreu
    Trugman, Joel M.
    CEPHALALGIA, 2023, 43 (1supp) : 47 - 49
  • [24] Eptinezumab for the preventive treatment of episodic and chronic migraine: a narrative review
    Irimia, Pablo
    Santos-Lasaosa, Sonia
    Pozo-Rosich, Patricia
    Leira, Rogelio
    Pascual, Julio
    Lainez, Jose Miguel
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [25] Gaps in the Acute Treatment of Episodic and Chronic Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study
    Lipton, Richard
    Manack, Aubrey
    Serrano, Daniel
    Buse, Dawn
    NEUROLOGY, 2013, 80
  • [26] Acute Treatment Optimization in Episodic and Chronic Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study
    Serrano, Daniel
    Buse, Dawn C.
    Adams, Aubrey Manack
    Reed, Michael L.
    Lipton, Richard B.
    HEADACHE, 2015, 55 (04): : 502 - 518
  • [27] Disability impact upon remission from chronic migraine to episodic migraine: results from the American migraine prevalence and prevention (AMPP) study
    Lipton, R. B.
    Manack, A.
    Buse, D. C.
    Serrano, D.
    Turkel, C. C.
    CEPHALALGIA, 2009, 29 : 72 - 72
  • [28] Assessing Barriers to Care in Episodic and Chronic Migraine: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
    Buse, D. C.
    Armand, C. E.
    Charleston, L.
    Reed, M. L.
    Fanning, K. M.
    Adams, Manack A.
    Lipton, R. B.
    HEADACHE, 2020, 60 : 61 - 62
  • [29] Assessing Barriers to Care in Episodic and Chronic Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
    Buse, Dawn C.
    Armand, Cynthia E.
    Charleston, Larry
    Reed, Michael L.
    Fanning, Kristina M.
    Adams, Aubrey Manack
    Lipton, Richard B.
    NEUROLOGY, 2021, 96 (15)
  • [30] Rates and reasons for discontinuation of triptans and opioids in episodic migraine: Results from the American Migraine Prevalence and Prevention (AMPP) study
    Holland, Starr
    Fanning, Kristina M.
    Serrano, Daniel
    Buse, Dawn C.
    Reed, Michael L.
    Lipton, Richard B.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2013, 326 (1-2) : 10 - 17
12345